Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SKRR Exploration Inc. V.SKRR

Alternate Symbol(s):  SKKRF

SKRR Exploration Inc. is a Canada-based precious metal explorer with properties in Saskatchewan mining jurisdictions. The Company's primary exploration focus is its three gold properties on the Trans-Hudson Corridor in Saskatchewan. The Company’s projects include Nickel Peak Group, Carp River, Manson Bay, Father Lake, Irving, Olson, Ithingo and Cathro. The Carp River property, comprised of five contiguous mineral claims totaling 5,606.48 hectares (ha), is located immediately north of the hamlet of Stony Rapids in the province of Saskatchewan. The 4,293 ha Manson Bay Project is located 40 kilometers (Km) northwest of Flin Flon, Manitoba’s historic mining center and four kilometers southwest of the Schotts Lake Copper-Zinc Deposit in Saskatchewan. The Father Lake property is located 40 km northeast of the hamlet of Stony Rapids in the province of Saskatchewan. The Ithingo Project consists of 12 contiguous mineral claims comprising an overall land package of approximately 2,849 hectares.


TSXV:SKRR - Post by User

Bullboard Posts
Post by DCArnoldon May 28, 2001 10:37pm
296 Views
Post# 3797802

My AGM impressions

My AGM impressions The power of the Internet: I was struck on several levels just how powerful and useful the Internet has become in a very short period of time. Most of the people that I met knew immediately who I am and what I do here. But that's not important to me, what is important is what Pat Pangburn was saying about how she found Biomira and the Theratope trial. Also how she recruited trial participants from all over America through her Internet connection. I think in the future it won't be quite as hard to get the clinical trial message out to patients. Dr. McPherson made a comment at the beginning of his presentation where he said that he preferred using chalk but even the good Dr. has adopted modern Internet technology: slideshows, webcasts and the like. The advantages of a community based trial like the Theratope phase III trial. I was discussing this point with the Dr.'s from the Midwest. They made the point that with 120 sites Biomira already has built the framework of a marketing structure. Many of the major oncology centers know about Theratope, they have experience with it and it won't be a new and unknown product to them. Also, if they want to do other trials, in say colorectal cancer, they already have made the contacts. It won't be quite as hard to recruit centers. Patients maybe but not centers. The partnership with Merck KGaA. The partnership is a superior deal, IMO, because of the control it gives Biomira over its own destiny. I've talked about this point before but I feel that it is important. Lukewitte55 made the point very well the other day when he said that no big US pharma would even have considered a deal like this. The leadership of Biomira is working to create a new entity, not just a R & D company but a fully integrated bio-pharma. It's a difficult step but a necessary one. Now that they've reached this point in development how could they even consider a deal that would cede control to another company? Of course they couldn't do that and they didn't. I'm sure we will be discussing this point in the future. Theratope trial design and chance of success at first look. I believe that the DSMB reviews have not been given the attention that they deserve. When Biomira first designed the phase III trial they made certain assumptions about the number of events that would occur at certain points in the trial. They have communicated these assumptions and numbers to the DSMB. They have said that at time X (X can be the 300, 600 or 800 patient level) we expect that there will be this number of patients who will have progressed and that there will be this number of patients who have died. If there are too many events at this time X, then Biomira's assumptions concerning the efficacy of Theratope could be called into question. Alternatively if there not enough events at these times then the assumptions concerning the control group could be called into question. It could mean that more time would be needed to show an effect. However the DSMB has not said either of these things. They have said, not once but three times that: "Having reviewed the safety data, the DSMB feels the trial should continue without any modifications." In other words Biomira's initial assumptions have been correct. BLP25 phase IIb trial. After attending the meeting and reading other reports I am convinced that the phase IIb trial will shortly be put on a faster track to full enrollment by Biomira and Merck KGaA by expanding the trial into the US. It is also possible (likely) that the number of patients will be increased in order to increase the possibility of the trial being potentially pivotal. Dr. McPherson himself said that the answer was obvious when answering Futurist2050's question. Merck has expressed the desire to introduce at least one new oncology product every year starting next year. Why partner with Biomira for Theratope and BLP25 if they were going to put BLP25 on the shelf because of slow enrollment in a large indication? That just doesn't make sense. Your fellow investor, DC Arnold
Bullboard Posts